1007882-59-8

Basic information

• Product Name: (S)-tert-butyl 2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate
• Synonyms: (S)-tert-butyl 2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate;tert-butyl (S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate;(S)-tert-butyl 2-(4-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate;tert-Butyl (S)-2-(4-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate;1-Pyrrolidinecarboxylic acid, 2-(5-bromo-1H-imidazol-2-yl)-, 1,1-dimethylethyl ester, (2S)-;tert-butyl (2S)-2-(4-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate;tert-butyl (2S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate;EOS-61040
• CAS NO: 1007882-59-8
• Molecular Formula: C₁₂H₁₈BrN₃O₂
• Molecular Weight: 316.19422
• EINECS: 1592732-453-0
• Mol File: 1007882-59-8.mol
• Article Data: 28

Chemical Properties

• Boiling Point: 469.3±35.0 °C(Predicted)
• Appearance: /
• Density: 1.444±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 11.13±0.10(Predicted)
• CAS DataBase Reference: (S)-tert-butyl 2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate(1007882-59-8)
• EPA Substance Registry System: (S)-tert-butyl 2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate(1007882-59-8)

Safety Data

• Hazardous Substances Data: 1007882-59-8(Hazardous Substances Data)

Usage

General Description

"(S)-tert-Butyl 2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate" is a chemical compound that consists of a pyrrolidine ring with a carboxylate ester group and a bromoimidazole substituent. The presence of the bromoimidazole group makes this compound useful as a building block in the synthesis of various pharmaceuticals and agrochemicals. It has also been identified as a potential inhibitor of certain enzymes and receptors, making it a valuable tool in biochemical research. The tert-butyl group provides stability and solubility to the molecule, making it easier to handle and use in a variety of applications. As a result, "(S)-tert-Butyl 2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate" is a versatile and important compound in the field of organic chemistry and drug discovery.

Upstream product

• 1007882-58-7 (S)-tert-butyl 2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 69610-41-9 Boc-L-Pro-H 
• 1240893-76-8 (S)-2-(4,5-dibromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 

Downstream Products

• 1007882-60-1 C₁₉H₂₁ClF₃N₃O₂ 
• 1007882-60-1 C₁₉H₂₁ClF₃N₃O₂ 
• 1246472-11-6 C₃₈H₄₃FN₆O₅ 
• 1228554-48-0 C₃₇H₄₃N₇O₅ 
• 1312610-05-1 C₃₈H₄₄N₆O₄S 
• 1312610-17-5 C₃₈H₄₄N₆O₅ 
• 1312610-23-3 C₃₉H₄₅N₇O₄ 
• 1312610-27-7 C₃₉H₄₅N₇O₄ 
• 1312611-69-0 C₂₉H₂₉N₇ 
• 1312610-32-4 C₃₉H₄₆N₆O₄S 
• 1312610-95-9 C₃₉H₄₇N₇O₄ 
• 1312611-03-2 C₂₅H₂₈N₄O₅ 
• 1312609-75-8 C₂₈H₂₉N₃O₃ 
• 1240893-76-8 (S)-2-(4,5-dibromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Peptidomimetics for Targeting Protein-Protein Interactions between DOT1L and MLL Oncofusion Proteins AF9 and ENL

MLL-fusion proteins, AF9 and ENL, play an essential role in the recruitment of DOT1L and the H3K79 hypermethylation of MLL target genes, which is pivotal for leukemogenesis. Blocking these interactions may represent a novel therapeutic approach for MLL-rearranged leukemia. Based on the 7 mer DOT1L peptide, a class of peptidomimetics was designed. Compound 21 with modified middle residues, achieved significantly improved binding affinities to AF9 and ENL, with KD values of 15 nM and 57 nM, respectively. Importantly, 21 recognizes and binds to the cellular AF9 protein and effectively inhibits the AF9-DOT1L interactions in cells. Modifications of the N- and C-termini of 21 resulted in 28 with 2-fold improved binding affinity to AF9 and much decreased peptidic characteristics. Our study provides a proof-of-concept for development of nonpeptidic compounds to inhibit DOT1L activity by targeting its recruitment and the interactions between DOT1L and MLL-oncofusion proteins AF9 and ENL.

9,9,10,10-TETRAFLUORO-9,10-DIHYDROPHENANTHRENE HEPATITIS C VIRUS INHIBITOR AND APPLICATION THEREOF

The present invention belongs to the field of chemical pharmaceuticals, and specifically relates to compounds represented by formula I having a 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene structure and being able to inhibit hepatitis C virus activity, or a pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug of said compounds, a pharmaceutical composition containing said compounds, and an application of said compounds or composition in the preparation of a drug. The compounds of the present invention have a good HCV inhibitory effect.